Nevro Receives FDA 510(k) Clearance To Use SI Fixation System Without Need To Include Lateral Screw
Portfolio Pulse from Benzinga Newsdesk
Nevro Corp. (NYSE:NVRO) announced FDA clearance for its Nevro1 sacroiliac joint fusion device, marketed as NevroFix, which can now be used without a lateral screw. This device, featuring self-contained, deployable titanium anchors and 3D-printed bone-growth technology, represents a significant advancement in SI fusion. This clearance follows Nevro's acquisition of Vyrsa Technologies in November 2023, enhancing its portfolio in the SI joint space.

February 28, 2024 | 9:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nevro Corp. received FDA clearance for its innovative Nevro1 device, marking a significant advancement in sacroiliac joint fusion technology. This development could enhance Nevro's market position and product portfolio in the chronic pain treatment sector.
The FDA clearance of Nevro1, a device that represents a significant advancement in SI joint fusion, is likely to positively impact Nevro Corp.'s stock price in the short term. This clearance not only enhances Nevro's product portfolio but also solidifies its position in the market for chronic pain treatment devices. The acquisition of Vyrsa Technologies and the integration of its products into Nevro's offerings further strengthen this outlook. Investors may view this regulatory approval as a sign of Nevro's continued innovation and growth potential in the medical device sector.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100